Intervention not reported
Daclizumab plus glucocorticosteroids (2 RCTs; 897 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (2 RCTs; 897 participants) (very low certainty).
1 finding from 1 review
OR 0.87 [0.65, 1.15]
Studies not reported
Very low
Intervention not reported
Anti‐thymocyte globulin plus glucocorticosteroids (1 RCT; 37 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes anti‐thymocyte globulin plus glucocorticosteroids (1 RCT; 37… (very low certainty).
1 finding from 1 review
Intervention not reported
Daclizumab plus glucocorticosteroids (1 RCT; 148 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (1 RCT; 148 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Daclizumab plus glucocorticosteroids (1 RCT; 698 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (1 RCT; 698 participants) (very low certainty).
1 finding from 1 review
HR 1.11 [0.44, 2.78]
Studies not reported
Very low
Intervention not reported
Glucocorticosteroids · adults undergoing liver transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Basiliximab plus glucocorticosteroids (1 RCT; 381 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes basiliximab plus glucocorticosteroids (1 RCT; 381 participants) (very low certainty).
1 finding from 1 review
OR 0.98 [0.02, 38.67]
Studies not reported
Very low
Intervention not reported
Anti‐thymocyte globulin plus glucocorticosteroids (1 RCT; 93 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes anti‐thymocyte globulin plus glucocorticosteroids (1 RCT; 93… (very low certainty).
1 finding from 1 review
Intervention not reported
Daclizumab plus glucocorticosteroids (3 RCTs; 1045 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (3 RCTs; 1045 participants) (very low certainty).
1 finding from 1 review
HR 1.26 [0.66, 2.42]
Studies not reported
Very low
Intervention not reported
Basiliximab plus glucocorticosteroids (1 RCT; 147 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes basiliximab plus glucocorticosteroids (1 RCT; 147 participants) (very low certainty).
1 finding from 1 review
OR 1.21 [0.52, 2.72]
Studies not reported
Very low
Intervention not reported
Daclizumab plus glucocorticosteroids (2 RCTs; 728 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (2 RCTs; 728 participants) (very low certainty).
1 finding from 1 review
OR 0.94 [0.67, 1.31]
Studies not reported
Very low
Intervention not reported
Basiliximab plus glucocorticosteroids (3 RCTs; 627 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes basiliximab plus glucocorticosteroids (3 RCTs; 627 participants) (very low certainty).
1 finding from 1 review
HR 0.72 [0.42, 1.15]
Studies not reported
Very low
Intervention not reported
Anti‐thymocyte globulin plus glucocorticosteroids (3 RCTs; 152 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes anti‐thymocyte globulin plus glucocorticosteroids (3 RCTs; 152… (very low certainty).
1 finding from 1 review
HR 1.72 [0.7, 4.28]
Studies not reported
Very low
Intervention not reported
Daclizumab plus glucocorticosteroids (5 RCTs; 1142 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (5 RCTs; 1142 participants) (very low certainty).
1 finding from 1 review
HR 1.33 [0.78, 2.43]
Studies not reported
Very low
Asthma exacerbations requiring hospitalisation or a course of steroids · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
Statins for asthma 2020 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Intervention not reported
Use of corticosteroids (proportion of patients using corticosteroids) · children with PFAPA
The intervention may leads to lower use of corticosteroids (proportion of patients using corticosteroids) (low certainty).
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in exacerbations requiring steroids or antibiotics or both: number of… compared with aclidinium alone (moderate certainty).
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in exacerbations requiring steroids or antibiotics or both: number of… compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to lower exacerbations requiring steroids or antibiotics or both: number of… compared with formoterol (high certainty).
1 finding from 1 review
Mean dose of inhaled corticosteroids per person per day (BUD equivalent mcg/day) · people with asthma
1 finding from 1 review
Mean daily use of oral corticosteroids per person per day · people with asthma
1 finding from 1 review